Skip Nav Destination
Issues
1 November 2009
-
Cover Image
Cover Image
Interphase alpha-tubulin immunostaining of human A549 epithelial lung cancer cells. The image shows vehicle-treated cells, which have a normal cytoplasmic tubulin distribution (green) and were well adherent. ALEXA 488 (green) was used to visualize the tubulin distribution; cell nuclei (red) were stained with propidium iodide. Cells treated with CYT997 for 1 hour had tubulin networks disrupted and had begun to dislodge. For details, see article by Burns and colleagues on page 3036. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Issue Sections
Spotlight on Clinical Response
A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies
Tanios S. Bekaii-Saab; Julie M. Roda; Kristan D. Guenterberg; Bhuvanaswari Ramaswamy; Donn C. Young; Amy K. Ferketich; Tammy A. Lamb; Michael R. Grever; Charles L. Shapiro; William E. Carson, III
Research Articles
Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents
Hiroshi Hirai; Yoshikazu Iwasawa; Megumu Okada; Tsuyoshi Arai; Toshihide Nishibata; Makiko Kobayashi; Toshifumi Kimura; Naoki Kaneko; Junko Ohtani; Kazunori Yamanaka; Hiraku Itadani; Ikuko Takahashi-Suzuki; Kazuhiro Fukasawa; Hiroko Oki; Tadahiro Nambu; Jian Jiang; Takumi Sakai; Hiroharu Arakawa; Toshihiro Sakamoto; Takeshi Sagara; Takashi Yoshizumi; Shinji Mizuarai; Hidehito Kotani
Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas
Kaiji Hu; Cathy Lee; Dexin Qiu; Abbas Fotovati; Alastair Davies; Samah Abu-Ali; Daniel Wai; Elizabeth R. Lawlor; Timothy J. Triche; Catherine J. Pallen; Sandra E. Dunn
CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo
Christopher J. Burns; Emmanuelle Fantino; Ian D. Phillips; Stephen Su; Michael F. Harte; Patricia E. Bukczynska; Mark Frazzetto; Max Joffe; Irma Kruszelnicki; Bing Wang; Yue Wang; Neil Wilson; Rodney J. Dilley; Soo S. Wan; Susan A. Charman; David M. Shackleford; Rosa Fida; Cathy Malcontenti-Wilson; Andrew F. Wilks
JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia
Carl L. Manthey; Dana L. Johnson; Carl R. Illig; Robert W. Tuman; Zhao Zhou; Judith F. Baker; Margery A. Chaikin; Robert R. Donatelli; Carol F. Franks; Lee Zeng; Carl Crysler; Yanmin Chen; Edward J. Yurkow; Lisa Boczon; Sanath K. Meegalla; Kenneth J. Wilson; Mark J. Wall; Jinsheng Chen; Shelley K. Ballentine; Heidi Ott; Christian Baumann; Danielle Lawrence; Bruce E. Tomczuk; Christopher J. Molloy
Letter to the Editor
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.